+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives



Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives



International Journal of Molecular Sciences 19(11)



Mammalian DNA topoisomerases II are targets of anticancer anthracyclines that act by stabilizing enzyme-DNA complexes wherein DNA strands are cut and covalently linked to the protein. This molecular mechanism is the molecular basis of anthracycline anticancer activity as well as the toxic effects such as cardiomyopathy and induction of secondary cancers. Even though anthracyclines have been used in the clinic for more than 50 years for solid and blood cancers, the search of breakthrough analogs has substantially failed. The recent developments of personalized medicine, availability of individual genomic information, and immune therapy are expected to change significantly human cancer therapy. Here, we discuss the knowledge of anthracyclines as Topoisomerase II poisons, their molecular and cellular effects and toxicity along with current efforts to improve the therapeutic index. Then, we discuss the contribution of the immune system in the anticancer activity of anthracyclines, and the need to increase our knowledge of molecular mechanisms connecting the drug targets to the immune stimulatory pathways in cancer cells. We propose that the complete definition of the molecular interaction of anthracyclines with the immune system may open up more effective and safer ways to treat patients with these drugs.

(PDF emailed within 0-6 h: $19.90)

Accession: 065693527

Download citation: RISBibTeXText

PMID: 30404148

DOI: 10.3390/ijms19113480


Related references

Chromosomal aberration and micronucleus studies of two topoisomerase (II) targeting anthracyclines. Journal of Environmental Biology 30(3): 409-412, 2010

Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?. European Journal of Cancer 44(18): 2791-2798, 2008

Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Research and Treatment 106(2): 181-189, 2007

Identification of early gene expression changes in primary cultured neurons treated with topoisomerase I poisons. Biochemical and Biophysical Research Communications 479(2): 319-324, 2016

Genetic elements suppressing human topoisomerase ii and inducing resistance to topoisomerase ii poisons. Proceedings of the American Association for Cancer Research Annual Meeting 33: 453, 1992

A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons. Journal of Biological Chemistry 270(11): 6141-6148, 1995

A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons. Journal of Biological Chemistry 275(11): 7980-7987, 2000

Modulation of topoisomerase I and IIalpha levels in tumour cells upon exposure to topoisomerase poisons. British Journal of Cancer 80(SUPPL 2): 50, 1999

Coordinating the two protomer active sites of human topoisomerase IIalpha: nicks as topoisomerase II poisons. Biochemistry 48(7): 1439-1441, 2009

Natural products as topoisomerase II poisons: effects of thymoquinone on DNA cleavage mediated by human topoisomerase II╬▒. Chemical Research in Toxicology 27(5): 787-793, 2015

Structure-activity relationship studies of 4- and 5-substituted terbenzimidazoles as topoisomerase I poisons. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 436-437, 1996

Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons. Current Pharmaceutical Design 8(22): 1945-1958, 2002

Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons. Bioorganic and Medicinal Chemistry 4(6): 781-791, 1996

Effect of 5-fluorouracil on DNA topoisomerase I cleavage complexes, cell cycle response and cytotoxicity induced by topoisomerase I poisons. Proceedings of the American Association for Cancer Research Annual Meeting 42: 508, 2001

Molecular characterization of recombinant Pneumocystis carinii topoisomerase I: differential interactions with human topoisomerase I poisons and pentamidine. Antimicrobial Agents and ChemoTherapy 46(7): 2145-2154, 2002